Perioperative drug therapy for muscle-invasive bladder cancer
Part of Cancer clinical trials.
This study looks at different drug treatments given around the time of surgery for muscle-invasive bladder cancer. It aims to understand how well these treatments work and may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with muscle-invasive bladder cancer (cancer that has grown into the bladder muscle).
- You have had, are having, or are scheduled to have drug therapy (such as chemotherapy or immunotherapy) before or after surgery.
- You are planning to have or have already had your bladder removed (radical cystectomy) as part of your treatment.
- You agree to allow your medical information to be used for research, and your records are complete enough for review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This study collects information from people with muscle-invasive bladder cancer who have had chemotherapy or immunotherapy and then decided not to have their bladder removed. It looks at different ways to preserve the bladder and how well those approaches work.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial tests a combination of probiotics, targeted therapy (RC48-ADC), and immunotherapy (Toripalimab) to treat muscle-invasive bladder cancer while preserving the bladder. The goal is to see if this combination can shrink or eliminate the cancer without needing bladder removal.
This study looks at nerve problems (peripheral neuropathy) in people with muscle-invasive bladder cancer who receive a combination of two drugs, enfortumab vedotin and pembrolizumab, before or after surgery. The goal is to understand how these treatments affect nerves and to help manage side effects.
This study looks at how chemotherapy given before bladder removal surgery changes the immune environment around the tumor. The goal is to see if these changes can help predict how well the treatment works, which could lead to better personalized care.
Hear when a new Urothelial Carcinoma of the Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.